Arena Pharmaceuticals (ARNA) Shares are Up 0.62%

Arena Pharmaceuticals (ARNA) has been under a strong bear grip, hence the stock is down -2.19% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 1.28% in the past 1 week. The stock has risen by 0.62% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.4% in the past 4 weeks.

Company shares have received an average consensus rating of Hold for the current week The stock has recorded a twenty day Moving Average of 2.03% and the fifty day Moving Average is 3.99%. Arena Pharmaceuticals, Inc. has dropped 6.86% during the last three month period . Year-to-Date the stock performance stands at -14.21%.

Arena Pharmaceuticals (ARNA) has been rated by 2 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $4 and the lowest price target forecast is $4. The average forecast of all the analysts is $3.75 and the expected standard deviation is $0.35.


Arena Pharmaceuticals (NASDAQ:ARNA): The stock was completely flat for the day, closing at $1.63 on Friday. The flat closing masks the intraday volatility in the stock. After opening at $1.63, the stock touched an intraday high of $1.66 and a low of $1.60. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $1.63. The total trading volume on Friday was 699,033.

Arena Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors (GPCRs). The Companys drug, BELVIQ (lorcaserin HCl), was approved by the United States Food and Drug Administration for marketing in the United States. In addition to BELVIQ, the Company has other drug candidates and compounds at various stages of research and development. The Company is exploring lorcaserins once-a-day, extended release formulation, as an aid to smoking cessation, in combination with phentermine and other agents for weight management, and for other possible indications. The Companys other drug candidates include ralinepag for vascular diseases, APD334 for autoimmune diseases, APD371 for pain and fibrotic diseases, and temanogrel for thrombotic diseases.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.